Approval of ACTISAVE design by the EMA to support a potential future marketing authorization application (MAA) for glenzocimab in Stroke Validation du choix d’un double critère d’évaluation principal : – Échelle de Rankin modifiée (mRS)1 – Échec (versus succès) défini par un […]

Strengthening discussions with regulatory authorities to accelerate the clinical development of glenzocimab for its potential benefit in the treatment of stroke 87 patients already enrolled in Europe in the ACTISAVE Phase 2/3 registration study in stroke patients ACTICOR BIOTECH (ISIN: […]